MedPal AI has launched what it believes to be a UK-first direct integration between a consumer health app and a regulated pharmacy, using AI to guide users into personalised, clinically supervised treatment pathways.
The AIM-listed digital health company’s app now uses AI to analyse aggregated user health data, including BMI, to identify individuals who may benefit from weight management support, GLP-1 treatments or other clinically prescribed medicines available through its online MedPal Clinic.
The system only directs users into clinical assessment pathways if they meet eligibility criteria, a move the company says ensures responsible targeting rather than broad advertising of weight loss drugs.
The integration operates entirely through the London-based firm’s AI backend, meaning no app update is required.
Eligible users are directed to MedPal Clinic’s online assessment, where prescriptions can be issued by independent prescribers.
THG Ingenuity split was right thing despite sleepless nights – Moulding
The business said the new functionality demonstrates its “dual-engine” business model, combining an AI-driven wellness app that generates demand with a regulated pharmacy operation that fulfils clinical needs.
It plans to extend the same AI-driven targeting approach across its wider pharmacy offering, including men’s and women’s health medications that can be prescribed under UK electronic prescription guidance.
The launch comes just a few months after the HealthTech’s IPO in late August.
Its share price now stands at 6.5p and it has a market cap of £27.78 million.
“We believe that this is a UK-first and that no other pharmacy has this depth of AI integration with a health app,” said Jason Drummond, CEO of MedPal AI.
“Our system doesn’t just advertise health supplements and weight loss treatments; it understands each user’s health profile and only connects those who clinically qualify with our GLP-1 prescribing services.
“This is the future of personalised healthcare, and MedPal is leading it.”